Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Key Points

• Martine Rothblatt, CEO of United Therapeutics, sold 4,000 shares of the company's stock for a total of $1,688,600, resulting in a 96.85% decrease in her ownership position.
• United Therapeutics reported earnings per share (EPS) of $6.41 for the last quarter, missing analyst estimates by $0.39, while its revenue was recorded at $798.6 million, up 11.7% year-over-year.
• Analysts have set a consensus target price of $461.62 for United Therapeutics, with several firms giving the stock a "buy" rating and price targets ranging from $500 to $580.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the business's stock in a transaction dated Wednesday, October 22nd. The stock was sold at an average price of $422.15, for a total transaction of $1,688,600.00. Following the sale, the chief executive officer directly owned 130 shares in the company, valued at approximately $54,879.50. This represents a 96.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Stock Performance

UTHR stock traded down $0.89 during trading on Wednesday, reaching $421.64. 463,682 shares of the company were exchanged, compared to its average volume of 593,352. The company has a market cap of $19.02 billion, a P/E ratio of 16.46, a PEG ratio of 4.72 and a beta of 0.66. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $459.48. The stock's 50 day moving average price is $390.76 and its 200 day moving average price is $329.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same quarter in the previous year, the firm posted $5.85 EPS. The business's revenue was up 11.7% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

Large investors have recently added to or reduced their stakes in the business. CWM LLC grew its holdings in United Therapeutics by 204.3% in the 2nd quarter. CWM LLC now owns 5,194 shares of the biotechnology company's stock valued at $1,492,000 after buying an additional 3,487 shares during the period. XTX Topco Ltd purchased a new position in shares of United Therapeutics during the 1st quarter worth about $313,000. Allianz Asset Management GmbH boosted its position in shares of United Therapeutics by 96.9% in the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock worth $20,832,000 after acquiring an additional 33,254 shares during the last quarter. LPL Financial LLC boosted its position in shares of United Therapeutics by 77.3% in the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock worth $7,783,000 after acquiring an additional 11,007 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in United Therapeutics by 11.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after purchasing an additional 376 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

UTHR has been the subject of several research reports. Royal Bank Of Canada began coverage on United Therapeutics in a research report on Friday, September 26th. They set an "outperform" rating and a $569.00 price objective for the company. HC Wainwright raised their price target on United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a research report on Friday, September 5th. UBS Group upped their price objective on United Therapeutics from $560.00 to $580.00 and gave the company a "buy" rating in a research report on Monday, September 29th. Cantor Fitzgerald increased their price objective on United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a research note on Wednesday, September 10th. Finally, Morgan Stanley lifted their price objective on United Therapeutics from $328.00 to $435.00 and gave the stock an "equal weight" rating in a research report on Friday, October 10th. Nine analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $461.62.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.